Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy
暂无分享,去创建一个
B. Zinman | R. Holman | R. Sherwin | D. Nathan | E. Ferrannini | J. Buse | M. Davidson
[1] B. Zinman,et al. Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy , 2009, Diabetes Care.
[2] L. Kennedy. Rosiglitazone Evaluated for Cardiovascular Outcomes—An Interim Analysis , 2008 .
[3] R. Nesto,et al. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials , 2007, The Lancet.
[4] Yoon K Loke,et al. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. , 2007, JAMA.
[5] A. Lincoff,et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. , 2007, JAMA.
[6] N. Marchionni,et al. Rosiglitazone and cardiovascular risk. , 2007, The New England journal of medicine.
[7] M. Hanefeld,et al. Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. , 2007, The New England journal of medicine.
[8] J. Drazen,et al. Rosiglitazone--continued uncertainty about safety. , 2007, The New England journal of medicine.
[9] Bruce M Psaty,et al. The record on rosiglitazone and the risk of myocardial infarction. , 2007, The New England journal of medicine.
[10] D. Nathan. Rosiglitazone and cardiotoxicity--weighing the evidence. , 2007, The New England journal of medicine.
[11] S. Nissen,et al. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.
[12] P. Cryer. Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement From the American Diabetes Association and the European Association for the Study of Diabetes , 2007, Diabetes Care.
[13] B. Zinman,et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. , 2006, The New England journal of medicine.
[14] S. Cummings,et al. Thiazolidinedione use and bone loss in older diabetic adults. , 2006, The Journal of clinical endocrinology and metabolism.
[15] R. Heine,et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy , 2006, Diabetologia.